Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6389486 | 0.98 | DGAT1 (0.57) | DGAT1IKBKBDDR1 | |
| SCHEMBL13312287 | 0.88 | DGAT1 (0.59) | DGAT1IKBKBDDR1 | |
| SCHEMBL3327674 | 0.88 | IKBKB (0.59) | DGAT1IKBKB | |
| SCHEMBL31198739 | 0.88 | IKBKB (0.63) | DGAT1IKBKB | |
| SCHEMBL162155 | 0.88 | DGAT1 (0.56) | DGAT1IKBKBDDR1 | |
| SCHEMBL16527465 | 0.88 | DGAT1 (0.47) | DGAT1IKBKB | |
| SCHEMBL27824154 | 0.86 | IKBKB (0.51) | DGAT1IKBKBDDR1 | |
| SCHEMBL3425573 | 0.85 | DGAT1 (0.46) | DGAT1IKBKBDDR1 | |
| SCHEMBL28793572 | 0.84 | KDM4E (0.61) | DGAT1 | |
| SCHEMBL16527581 | 0.82 | NPC1 (0.48) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| CN-101835757-B | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE | 2014-03-05 | — | — | CN | claimed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | claimed |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | claimed |
| US-8211884-B2 | 2,2-Dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-butyric acid, hydrochloride; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| CN-102245024-A | Inhibitors of diacylglycerol aclytransferase | VIA PHARMACEUTICALS INC | 2011-11-16 | — | — | CN | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | DGAT1 3152/4885IKBKB 648/4885DDR1 1656/4885 |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | DGAT1 1485/4885IKBKB 1788/4885DDR1 3862/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | DGAT1 2488/4885IKBKB 3808/4885DDR1 4704/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | DGAT1 1485/4885IKBKB 1788/4885DDR1 3862/4885 |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | HTR5A, HTR2A, HTR1A | DGAT1 1485/4885IKBKB 1788/4885DDR1 3862/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | DGAT1 3152/4885IKBKB 648/4885DDR1 1656/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | DGAT1 3152/4885IKBKB 648/4885DDR1 1656/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | DGAT1 3152/4885IKBKB 648/4885DDR1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.